48 results about "Colonic contents" patented technology

The field of colonic diagnostic and surgical procedures is hampered by the lack of optimal means available to cleanse the colon. A compromise between convenient, distasteful, solid or low volume, hyperosmotic solutions which cause considerable fluid and electrolyte imbalances in patients and large volume, difficult to consume, iso-osmotic solutions has had to be made heretofore. This invention describes a low volume, hyper-osmotic solution consisting of sulfate salts with and with out polyethylene glycol. Unlike prior art, this composition is useful for the cleansing of the bowel and, in lower volumes, as a laxative, without producing clinically significant changes in bodily function.

The invention provides a compressed pharmaceutical composition comprising polyethylene glycol of molecular weight from 2000 to 4500, wherein the polyethylene glycol makes up from 80 to 99.5% by weight of the composition, one or more electrolytes for the treatment of constipation, faecal impaction, faecal retention, intestinal gas and cramping, or flatulence; or for orthostatic lavage, colon evacuation or colon cleansing. It has been found, surprisingly, that a compressed pharmaceutical composition comprising PEG for example a solid tablet, is significantly more palatable than previously proposed compositions and is effective when administered. The compressed pharmaceutical composition of the invention comprising polyethylene glycol has been found to have a more agreeable taste and a more agreeable mouthfeel than previously proposed liquid or dry powder or granular compositions.

A system for performing a virtual colonoscopy includes a system for generating digital images, a storage device for storing the digital images, a digital bowel subtraction processor coupled to receive images of a colon from the storage device and for removing the contents of the colon from the image and an automated polyp detection processor coupled to receive images of a colon from the storage device and for detecting polyps in the colon image.

Apparatus for effecting colonic transit having a pad, defining a guide groove to overly the abdomen of a person, a roller, movable along the guide groove to apply pressure progressively along the groove to effect movement of colonic contents along the colon. The guide groove may be defined in a pad or may be defined by ridges extending outwardly of a member such as a pad. The roller may comprise a handle and a roller wheel, with the wheel preferably swivelly mounted relative to the handle.

Stimulant laxative in combination with an osmotic laxative produces safe and effective bowel and colon cleansing with a reduced volume of liquid input. Administering to a patient an oral stimulant laxative, such as bisacodyl, followed, after a biologically determined interval, by a reduced volume of a PEG in water solution cleanses the bowels and colon in preparation for diagnostic colonoscopy, without the profuse uncontrollable diarrhea that typically follows either ingestion of large volume isotonic ravages, or smaller volume hypertonic lavages.

The invention provides a compressed pharmaceutical composition comprising polyethylene glycol of molecular weight from 2000 to 4500, wherein the polyethylene glycol makes up from 80 to 99.5% by weight of the composition, one or more electrolytes for the treatment of constipation, faecal impaction, faecal retention, intestinal gas and cramping, or flatulence; or for orthostatic lavage, colon evacuation or colon cleansing. It has been found, surprisingly, that a compressed pharmaceutical composition comprising PEG for example a solid tablet, is significantly more palatable than previously proposed compositions and is effective when administered. The compressed pharmaceutical composition of the invention comprising polyethylene glycol has been found to have a more agreeable taste and a more agreeable mouthfeel than previously proposed liquid or dry powder or granular compositions.

Stimulant laxative in combination with an osmotic laxative produces safe and effective bowel and colon cleansing with a reduced volume of liquid input. Administering to a patient an oral stimulant laxative, such as bisacodyl, followed, after a biologically determined interval, by a reduced volume of a PEG in water solution cleanses the bowels and colon in preparation for diagnostic colonoscopy, without the profuse uncontrollable diarrhea that typically follows either ingestion of large volume isotonic lavages, or smaller volume hypertonic lavages.

A composition comprising, per litre of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate, preferably from 1 to 15 g thereof, and optionally one or more electrolytes selected from sodium chloride, potassium chloride, and sodium hydrogen carbonate, and preferably also comprising flavourings, is effective in cleansing the gut in preparation for a endoscopy, especially colonoscopy. It is safer than conventional sodium phosphate-based gut cleansing compositions, and hence can be used for patients who would be at risk with sodium phosphate-based compositions, and is better tolerated than conventional PEG-based compositions, leading to better patient compliance and enabling effective out-patient use.

This invention relates, e.g., to a composition comprising two or more of: (a) N-acetylcysteine and / or (b) simethicone and / or (c) a docusate salt. In one embodiment of the invention, the amounts of (a) and / or (b) and / or (c) are effective, when the composition is administered into a colon of a subject undergoing colonoscopy, to cleanse a region of the colon in the visual field of the colonoscope so that the region contains no adherent stool or intestinal secretions obscuring the visual field. Methods for using this or other compositions of the invention, e.g. to cleanse the colon of a subject in order to enhance visualization of the colon during a colonoscopy, are also described, as are kits for carrying out methods of the invention.

A composition comprising, per litre of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate, preferably from 1 to 15 g thereof, and optionally one or more electrolytes selected from sodium chloride, potassium chloride, and sodium hydrogen carbonate, and preferably also comprising flavourings, is effective in cleansing the gut in preparation for a endoscopy, especially colonoscopy. It is safer than conventional sodium phosphate-based gut cleansing compositions, and hence can be used for patients who would be at risk with sodium phosphate-based compositions, and is better tolerated than conventional PEG-based compositions, leading to better patient compliance and enabling effective out-patient use.

A composition and method for cleansing a colon prior to endoscopic procedure. More particularly, a combination of bisacodyl, metoclopramide, sodium, and / or a phosphorus containing composition administered in sequential doses for preparing a colon prior to colonoscopy.

A method of colon cleansing that provides superior cleansing. In an embodiment, superior cleansing of the right colon is provided. In an embodiment, a stimulant laxative is consumed at least two days prior to the day for which maximum cleansing is desired, and an osmotic purgative is consumed one day prior to the day for which maximum cleansing is desired. A regimen that administered PICO-SALAX® plus BISACODYL™ was superior in cleansing the right colon compared to PICO-SALAX® alone, and when compared to Oral Sodium Phosphate. Patient tolerability and safety were excellent.

The invention relates to sea buckthorn calcium and a preparation method thereof, wherein, the sea buckthorn calcium comprises the following ingredients by weight percentage: calcium fruit powders accounting for 40 to 60 percent, sea buckthorn powders accounting for 10 to 30 percent, asparagus powders accounting for 10 to 25 percent and collagen protein powders accounting for 5 to 20 percent. The sea buckthorn calcium and the preparation method thereof can achieve better calcium absorption efficiency, can also achieve the efficacies of cancer prevention and treatment as well as beauty, and canachieve the auxiliary efficacies lowering cholesterol and blood fat, enhancing blood vessel elasticity, lowering blood pressure, reducing platelet aggregation and reducing heart attack. The sea buckthorn calcium and the preparation method thereof can regulate hyperglycemia, can reduce diabetic shock, and can reduce the attack probability of rectal cancer and gastric cancer. Sea buckthorn calcium can be combined with fat, so that the effects of colon cleansing, detoxication and blood cleaning can be achieved, and impurities in human bodies can be eliminated. The sea buckthorn calcium is particularly suitable for being taken by middleaged and elderly people, patients suffered from high blood pressure, hyperlipidemia, diabetes and hyperglycemia and the people easy to catch a cold.

This invention relates, e.g., to a composition comprising two or more of: (a) N-acetylcysteine and / or (b) simethicone and / or (c) a docusate salt. In one embodiment of the invention, the amounts of (a) and / or (b) and / or (c) are effective, when the composition is administered into a colon of a subject undergoing colonoscopy, to cleanse a region of the colon in the visual field of the colonoscope so that the region contains no adherent stool or intestinal secretions obscuring the visual field. Methods for using this or other compositions of the invention, e.g. to cleanse the colon of a subject in order to enhance visualization of the colon during a colonoscopy, are also described, as are kits for carrying out methods of the invention.

The invention provides a colon cleansing solution comprising:a) 300 to 800 mmol per litre ascorbate anion provided by a mixture of:(i) ascorbic acid and(ii) one or more salts of ascorbic acidthe components (i) and (ii) being present in a molar ratio of from 1:4.5 to 1:7.0; andb) 10 to 200 g per litre polyethylene glycol.The invention also provides methods an kits associated with, or making use of the solutions, and compositions for the preparation of the solutions.

A composition and method for cleansing a colon prior to endoscopic procedure. More particularly, a combination of bisacodyl, metoclopramide, sodium, and / or a phosphorus containing composition administered in sequential doses for preparing a colon prior to colonoscopy.

The invention provides an automatic medical temperature control colon cleansing device which comprises a power circuit, a power drive circuit, a heater and a thermistor which are all electrically connected. A test probe of the thermistor stretches into the heater. The automatic medical temperature control colon cleansing device further comprises a single chip microcomputer connected with the power drive circuit in a control mode. The two ends of the thermistor are connected to a same-direction input end and a reverse-direction input end of an operational amplifier respectively. An output end of the operational amplifier is connected to a voltage signal acquisition pin of the single chip microcomputer. An output duty ration pin of the single chip microcomputer is connected to the power drive circuit. The heater is powered to heat liquid and raises the temperature of the liquid. The resistance value of the thermistor changes along with changes of the temperature of the heater. The resistance value changing along with changes of the temperature is converted into a voltage value and the voltage value is then amplified and converted. The power loaded on the heater is controlled and adjusted according to the processing result so as to adjust the temperature of the liquid, and the purposes of automatic detection and temperature control are achieved; meanwhile, the acquired voltage signals are more accurate through introduction of the digital acquisition technology, and temperature control accuracy is improved.

A composition comprising, per litre of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate, preferably from 1 to 15 g thereof, and optionally one or more electrolytes selected from sodium chloride, potassium chloride, and sodium hydrogen carbonate, and preferably also comprising flavourings, is effective in cleansing the gut in preparation for a endoscopy, especially colonoscopy. It is safer than conventional sodium phosphate-based gut cleansing compositions, and hence can be used for patients who would be at risk with sodium phosphate-based compositions, and is better tolerated than conventional PEG-based compositions, leading to better patient compliance and enabling effective out-patient use.

The present invention can provide: a colon purgation tablet having a gel-forming coating layer containing an alginate as a main component, the gel-forming coating layer being introduced into an uncoated tablet containing an osmotic substance, the present invention relates to an uncoated tablet, and more particularly, to an uncoated tablet, such that the osmotic substance contained in the uncoated tablet disintegrates rapidly while preventing damage to gastric mucosa due to a physical collision between the tablet and the gastric mucosa, and thus provides an excellent intestinal cleansing effect. The colon purgation tablet according to the present invention can exhibit an excellent intestinal cleansing effect even at a small dose, and can further improve drug compliance by selectively miniaturizing the tablet or introducing an adhesive to improve a coating layer.

The present invention provides peptides and compositions useful in the treatment of gastrointestinal disorders or for colon cleansing. The invention also provides compositions and methods for treating gastrointestinal disorders and pharmaceutical compositions for implementing the same. In some embodiments, the pharmaceutical compositions include oral dosage forms.

Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.

To provide peptides and compositions useful for treatment of gastrointestinal disorders or for colon cleansing.SOLUTION: The present invention provides compositions and methods of treating gastrointestinal disorders as well as pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms. The present invention features peptides, compositions and related methods for colon cleansing treatment as well as other conditions and disorders described herein. In one embodiment, the peptides may be used to prepare subjects for colonoscopy treatment. In some embodiments, the peptides or pharmaceutically acceptable salts may be used to prepare subjects for surgery, such as bowel surgery.SELECTED DRAWING: None

The present invention relates to a colon cleansing composition with improved ease of administration. The composition minimizes side effects caused by excessive ingredient content in conventional colonic laxatives while providing equivalent or superior intestinal cleansing efficacy, thereby remarkably improving patient compliance and ingestion convenience. In addition, as an uncoated tablet requiring no separate coating processes, a preparation that maintains the quality of tablets such as rapid disintegration and does not have a bitter taste can be provided. The present invention provides a pharmaceutical formulation comprising the colon cleansing composition with improved ease of administration and a method for colon cleansing using the formulation, thereby realizing a patient-centered colon cleansing process and ultimately greatly contributing to the improvement of colonoscopy quality.

Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.

The invention provides a pig intestine cleaning device, and belongs to the field of livestock and poultry processing devices. The pig intestine cleaning device comprises a four-leg support body, a cleaning area is arranged on the support body, sliding rods are arranged on two sides of the cleaning area, a penetrating rod seat is arranged above the cleaning area, an intestine fixing seat sleeves on an intestine penetrating rod, an adjusting motor I is arranged on one side of the cleaning area, a driving shaft of the adjusting motor is connected with a lead screw, a sliding seat is arranged on the lead screw, and a connecting seat is arranged on the sliding seat and connected with the cleaning seat through a connecting shaft. The pig intestine cleaning device has the advantages that pig intestines can be mostly and automatically cleaned, manpower and labor force are saved, working efficiency is improved, and production is facilitated.

The present invention provides an oligonucleotide comprising the sequence 5 '-GGAACAGTTCGTCCATGGC-3' (SEQ ID NO: 2) for use in the treatment of inflammatory bowel disease in a human subject by topical administration to the colon wherein the subject has not been subjected to colon cleansing prior to said administration.

A method for electronically cleansing a virtual object formed from acquired image data converted to a plurality of volume elements is provided. The present method allows individual volume elements, or voxels, to represent more than one material type. The method includes defining a partial volume image model for volume elements representing a plurality of material types based, at least in part, on the measured intensity value of the volume element. The material mixture for each of the volume elements representing a plurality of material types can be estimated using the observed intensity values and the defined partial volume image model. The volume elements representing a plurality of material types can then be classified in accordance with the estimated material mixture. For electronic colon cleansing, the method includes removing at least one classification of volume elements when displaying the virtual object.

The application discloses a lactobacillus rhamnosus capable of significantly increasing the number of enteric neurons and neuroglial cells and an application thereof, and belongs to the field of microorganisms.The lactobacillus rhamnosus CCFM1360 has good activity, certain acid and alkali resistance and adhesion, can significantly increase the number of enteric neurons and neuroglial cells, repair intestinal barrier function, increase the content of SCFAs in colon contents, increase the number of Treg cells in mesenteric lymph nodes, reduce the expression level of inflammatory factors in colon tissues, reduce the intestinal inflammation level, and relieve the weakened intestinal motility disorder.

Disclosed herein are methods of administering compositions comprising a mixture of salts that induce purgation of the colon and are useful to cleanse the colon. Furthermore, the disclosed methods prevent degradation of PEG and allow for cleansing of the colon without the use of adjunct laxatives, including stimulant laxatives such as bisacodyl. The disclosed methods are superior to the prior art in that they allow for higher tolerability, improved safety, lower volumes, and improved patient compliance.